| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Gena Wang downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and lowers the pric...
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate o...
-SEC Filing
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $...
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate o...
https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-research